PL415392A1 - Protein sequence, preferably a fragment of antibody, constituting VEGF-C inhibitor and its application - Google Patents

Protein sequence, preferably a fragment of antibody, constituting VEGF-C inhibitor and its application

Info

Publication number
PL415392A1
PL415392A1 PL415392A PL41539215A PL415392A1 PL 415392 A1 PL415392 A1 PL 415392A1 PL 415392 A PL415392 A PL 415392A PL 41539215 A PL41539215 A PL 41539215A PL 415392 A1 PL415392 A1 PL 415392A1
Authority
PL
Poland
Prior art keywords
vegf
inhibitor
application
protein sequence
antibody
Prior art date
Application number
PL415392A
Other languages
Polish (pl)
Other versions
PL234874B1 (en
Inventor
Monika Bzowska
Małgorzata Kulesza
Renata Mężyk-Kopeć
Tomasz Klaus
Barbara Wyroba
Joanna Bereta
Original Assignee
Uniwersytet Jagielloński
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Jagielloński filed Critical Uniwersytet Jagielloński
Priority to PL415392A priority Critical patent/PL234874B1/en
Publication of PL415392A1 publication Critical patent/PL415392A1/en
Publication of PL234874B1 publication Critical patent/PL234874B1/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Zgłoszenie dotyczy nowych sekwencji białkowych, hamujących biologiczną aktywność czynnika wzrostu śródbłonka naczyniowego C (VEGF-C), będących inhibitorami VEGF-C. W szczególności, sekwencji białkowych, stanowiących jednołańcuchowe fragmenty ludzkich przeciwciał (scFv), wiążących się z VEGF-C i neutralizujących jego działanie. Zgłoszenie także dotyczy sposobu hamowania limfangiogenezy, który to sposób obejmuje podawanie do organizmu odpowiedniej ilości sekwencji białkowej stanowiącej inhibitor VEGF-C oraz zastosowania tego inhibitora.The application relates to new protein sequences that inhibit the biological activity of vascular endothelial growth factor C (VEGF-C), which are VEGF-C inhibitors. In particular, protein sequences that are single chain human antibody (scFv) fragments that bind to and neutralize VEGF-C. The application also relates to a method of inhibiting lymphangiogenesis, which method comprises administering to the body an appropriate amount of a VEGF-C inhibitor protein sequence and the use of this inhibitor.

PL415392A 2015-12-28 2015-12-28 Protein sequence, preferably a fragment of antibody, constituting VEGF-C inhibitor and its application PL234874B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL415392A PL234874B1 (en) 2015-12-28 2015-12-28 Protein sequence, preferably a fragment of antibody, constituting VEGF-C inhibitor and its application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL415392A PL234874B1 (en) 2015-12-28 2015-12-28 Protein sequence, preferably a fragment of antibody, constituting VEGF-C inhibitor and its application

Publications (2)

Publication Number Publication Date
PL415392A1 true PL415392A1 (en) 2017-07-03
PL234874B1 PL234874B1 (en) 2020-04-30

Family

ID=59201275

Family Applications (1)

Application Number Title Priority Date Filing Date
PL415392A PL234874B1 (en) 2015-12-28 2015-12-28 Protein sequence, preferably a fragment of antibody, constituting VEGF-C inhibitor and its application

Country Status (1)

Country Link
PL (1) PL234874B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022238459A1 (en) * 2021-05-11 2022-11-17 Centre National De La Recherche Scientifique (Cnrs) New humanized anti-vegfc antibodies and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022238459A1 (en) * 2021-05-11 2022-11-17 Centre National De La Recherche Scientifique (Cnrs) New humanized anti-vegfc antibodies and uses thereof

Also Published As

Publication number Publication date
PL234874B1 (en) 2020-04-30

Similar Documents

Publication Publication Date Title
PH12019502459A1 (en) Anti-trem2 antibodies and methods of use thereof
PH12018501220A1 (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
SA518390944B1 (en) Tissue factor pathway inhibitor antibodies and uses thereof
JOP20160131B1 (en) Factor xi antibodies and methods of use
EA201890428A1 (en) INHIBITORS OF CONTROL POINTS OF IMMUNE RESPONSE FOR APPLICATION IN THE TREATMENT OF DIFFERENT TYPES OF CANCER OF THE BLOOD
EA201792221A1 (en) ANTIBODIES AGAINST SORTILINE AND METHODS OF THEIR APPLICATION
PH12016502064A1 (en) Human antibodies to middle east respiratory syndrome-coronavirus spike protein
AR104280A1 (en) COMBINATION THERAPY WITH COAGULATION FACTORS AND MULTI-SPECIFIC ANTIBODIES
CY1117655T1 (en) FACTORS AFFECTING CANCER AND IMMUNE AND AUTOMATIC DISEASES TREATMENT
CY1116728T1 (en) FACTORS AFFECTING CANCER AND IMMUNE AND AUTOMATIC DISEASES TREATMENT
EA201890305A1 (en) HUMANIZED OR CHIMERIC CD3 ANTIBODIES
EA201791168A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR EYE DISEASES
PE20181054A1 (en) HUMANIZED ANTI-CD19 ANTIBODIES AND METHODS OF USE
UA113623C2 (en) TISSUE FACTOR FACTOR (TFPI) MONOCLONAL ANTIBODY AGAINST TISSUE FACTOR INHIBITOR
CY1121734T1 (en) MUTANT OspA FRAGMENTS AND METHODS AND USES THEREOF
EA202190138A1 (en) ANTI-SIRP-BETA1 ANTIBODIES AND METHODS OF THEIR USE
MX2019009498A (en) Fgf21 mimetic antibodies and uses thereof.
EA202190183A1 (en) ANTIBODIES TO SIGLEC-5 AND METHODS OF THEIR APPLICATION
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
BR112016023011A2 (en) gastric cancer treatment
MX2021003298A (en) Methods of reversing ticagrelor activity.
EA202090266A1 (en) MPO INHIBITORS FOR MEDICAL USE
PL415392A1 (en) Protein sequence, preferably a fragment of antibody, constituting VEGF-C inhibitor and its application
MX2020011377A (en) Methods and compositions for treating chronic urticaria.
PL415391A1 (en) Protein sequence, preferably constituting a fragment of antibody, in a specific way interacting with human or mouse vascular endothelial growth factor C, and its application